Value of pretreatment DPYD genotyping in gastrointestinal oncology: An analysis of cost avoidance and healthcare utilization.
39 Background: Fluoropyrimidines are foundational agents in GI oncology, however they can cause severe toxicity in patients with reduced dihydropyrimidine dehydrogenase (DPD) activity due to pathogenic DPYD variants. Pretreatment DPYD genotyping enables identification of at-risk patients and supports genotype-g...